dabigatran - omeprazol
dabigatran - omeprazol
Klass : B3
Visa all info
Skriv ut
Kontakta oss
Pradaxa (dabigatran). Boehringer Ingelheim. SPC, EPAR [www]. 2008.
Kuwayama T, Osanai H, Ajioka M, Tokuda K, Ohashi H, Tobe A et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm. 2017;33:619-623.
Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9:2168-75.
Ollier E, Hodin S, Basset T, Accassat S, Bertoletti L, Mismetti P et al. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol. 2015.
Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555-63.
Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47-59.
Schnierer M, Samoš M, Bolek T, et al. The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etexilate Plasma Levels in Patients With Atrial Fibrillation: A Washout Study. J Cardiovasc Pharmacol. 2020 Apr;75(4):333-5.
Bolek T, Samoš M, Stančiaková L, Ivanková J, Škorňová I, Staško J et al. The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. Am J Ther. 2019 May/Jun;26:e308-e313.
Bolek T, Samoš M, Škorňová I, Schnierer M, Lipták P, Bánovčin P et al. Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?. Eur J Clin Pharmacol. 2019;75:875-877.
- Pradaxa (dabigatran). Boehringer Ingelheim. SPC, EPAR [www]. 2008.
- Kuwayama T, Osanai H, Ajioka M, Tokuda K, Ohashi H, Tobe A et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm. 2017;33:619-623.
- Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9:2168-75.
- Ollier E, Hodin S, Basset T, Accassat S, Bertoletti L, Mismetti P et al. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol. 2015.
- Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555-63.
- Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47-59.
- Schnierer M, Samoš M, Bolek T, et al. The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etexilate Plasma Levels in Patients With Atrial Fibrillation: A Washout Study. J Cardiovasc Pharmacol. 2020 Apr;75(4):333-5.
- Bolek T, Samoš M, Stančiaková L, Ivanková J, Škorňová I, Staško J et al. The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. Am J Ther. 2019 May/Jun;26:e308-e313.
- Bolek T, Samoš M, Škorňová I, Schnierer M, Lipták P, Bánovčin P et al. Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?. Eur J Clin Pharmacol. 2019;75:875-877.